

**Supplementary Information for:**

***Coxiella* co-opts the Glutathione Peroxidase 4 (GPX4) to protect the host cell from oxidative stress-induced cell death**

Robson Kriiger Loterio<sup>1,2</sup>, David R. Thomas<sup>2,3</sup>, Warrison Andrade<sup>1</sup>, Yi Wei Lee<sup>2</sup>, Leonardo Lima dos Santos<sup>1</sup>, Danielle P. A. Mascarenhas<sup>1</sup>, Thiago Maass Steiner<sup>2</sup>, Jéssica Chiaratto<sup>4</sup>, Laura F. Fielden<sup>2,5</sup>, Leticia Lopes<sup>1</sup>, Lauren E. Bird<sup>2</sup>, Gustavo Henrique Goldman<sup>4</sup>, Diana Stojanovski<sup>5</sup>, Nichollas E. Scott<sup>2</sup>, Dario Simões Zamboni<sup>1#</sup> & Hayley J. Newton<sup>2,3#</sup>.

# corresponding authors

Email: dszamboni@fmrp.usp.br and hayley.newton@monash.edu

**This PDF file includes:**

Supplementary text  
Figure S1 to S2  
Tables S1 to S2  
SI References

39 **Supplementary Information Text**

40 **Extended Methods:**

41

42 **Bacterial culture and preparation**

43 *Escherichia coli* DH5 $\alpha$  (Clontech) was grown in Luria–Bertani medium  
44 supplemented with 50  $\mu$ g/mL kanamycin (Sigma–Aldrich), with 100  $\mu$ g/mL  
45 ampicillin (A. G. Scientific) or with 10  $\mu$ g/mL chloramphenicol (Boehringer  
46 Mannheim) when required.

47

48 *L. pneumophila* JR32  $\Delta$ *flaA* strains were used in this study as previously described  
49 <sup>32,77</sup>. Bacteria were cultured on ACES buffered charcoal-Yeast Extract Agar <sup>32</sup> at  
50 37°C, for 4 days from frozen stocks. Single colonies were streaked on fresh plates  
51 containing Isopropyl  $\beta$ - d-1-thiogalactopyranoside (IPTG) and allowed to grow for  
52 another 2 days. For *in vitro* and *in vivo* infections, bacteria grown on BCYE agar  
53 plates were resuspended in sterile distilled water and diluted in RPMI to the  
54 required density based on OD600 nm.

55

56 *C. burnetii* Nine Mile Phase II RSA439 (Ted Hackstadt, NIH), referred to as wild  
57 type (WT),  $\Delta$ *mceF*,  $\Delta$ *mceF* pFLAG:*mceF* [pJB-CAT:3xFLAG\_*mceF*] and the  
58 T4BSS mutant *lcmL* were routinely cultivated in ACCM-2 as previously described  
59 <sup>78,79</sup>. The media was supplemented with 350  $\mu$ g/ml kanamycin or 3  $\mu$ g/ml  
60 chloramphenicol when required and cultures incubated at 37°C, 5% CO<sub>2</sub>, 2.5% O<sub>2</sub>.

61

62 **Construction of *L. pneumophila* expressing *C. burnetii* effectors**

63 *L. pneumophila* JR32  $\Delta$ *flaA* were electroporated with pJB-CAT:3xFLAG  
64 constructs, cloned individually with Dot/Icm effectors from *C. burnetii*. Briefly, a 2-  
65 day patch of *L. pneumophila* was resuspended in 10 mL of ice-cold 10% glycerol  
66 and centrifuged at 3,220 x g for 5 minutes at 4°C, then washed twice with 10 mL  
67 ice-cold 10% glycerol. Bacterial pellets were resuspended in 50  $\mu$ L ice-cold 10%  
68 glycerol and stored at -80°C long term. Cells were electroporated with 100-500 ng  
69 of plasmid DNA at 2.5 kV, 25  $\mu$ F and 200  $\Omega$  in a BioRad Gene Pulse XCell and  
70 immediately resuspended in 950  $\mu$ L of ACES-buffered Yeast Extract. Effector

71 expression of transformed *L. pneumophila* was amplified with the addition of 1 mM  
72 of isopropyl b-D-1-thiogalactopyranoside (IPTG, Invitrogen) to agar plates and  
73 confirmed by immunoblot using an anti-FLAG antibody (Sigma-Aldrich).

74

#### 75 **BlaM:CBU1543 plasmid construction**

76 Plasmids pJB-CAT:BlaM-MCS and pcDNA4/TO:3xFLAG:CBU1543 were digested  
77 with BamHI and XhoI, CIP treated, and gel purified. The *cbu1543* fragment was  
78 ligated into the digested vector and transformed into PIR2 *E. coli*. Plasmids were  
79 confirmed by sequencing. The newly created plasmid, pJB-CAT:BlaM:CBU1543,  
80 was then transformed into WT and *lcmL* mutant *C. burnetii* NMII and clonally  
81 isolated. Expression of the fusion protein was confirmed by western blot. WT and  
82 *lcmL* mutant *C. burnetii* NMII expressing pJB-CAT:BlaM:CBU0077(MceA) were  
83 used as a positive control.

84

#### 85 **Translocation assay**

86 Translocation assays were performed using the LiveBLAzer FRET loading kit  
87 (Thermo Fisher Scientific) as previously described <sup>1</sup> and according to  
88 manufacturer's instructions. Briefly, HeLa CCL2 cells were seeded in black-walled  
89 clear bottom plates and infected with the relevant *C. burnetii* strains at an MOI of  
90 500 the next day. After 20 hours, cells were treated with 2 mM MnCl<sub>2</sub> for 2 hours  
91 before loading with CCF2-AM and incubating at room temperature for a further 2  
92 hours. Plates were read on a Clariostar plate reader. Ratios of fluorescence at 520  
93 and 450 were calculated after subtracting background fluorescence from cell-free  
94 wells, with an increase in ratio corresponding to an increase in translocation.

95

#### 96 **Recombinant DNA and molecular biology**

97 See Table S2 for oligonucleotides used in this study. Pfu Ultra was used to amplify  
98 DNA for cloning and GoTaq® Green (Promega) or MyTaq™ Red (Bioline) were  
99 used to screen *E. coli* colonies with inserts >1 kb or <1 kb, respectively, according  
100 to the manufacturer's protocol. Samples were sequenced using the Sanger  
101 method by AGRF (Australian Genome Research Facility). Analysis of the results

102 was conducted using Sequencher (Gene Codes Corporation) and compared to  
103 known GenBank sequences using BLAST <sup>2</sup>.

104

105 The library of *C. burnetii* effector expression plasmids was constructed using  
106 oligonucleotides listed in Table S1 and In-Fusion cloning protocols (BD Clontech)  
107 or traditional restriction enzyme cloning. pJB-CAT3xFLAG and genomic DNA for  
108 *C. burnetii* Dugway 5J108-111, G Q212 and K Q154 were kindly provided by Prof  
109 Bob Heinzen.

110

### 111 **Stable cell lines**

112 Stable doxycycline-inducible HeLa cells were generated using a lentiviral system  
113 to introduce pTRE\_3G or pTRE\_3G:3xFLAG:*mceF* (plasmids are listed in Table  
114 S1). Briefly, 10 cm dishes (Corning) containing HEK293T cells in DMEM + 10%  
115 FCS were co-transfected with pTRE\_3G:3xFLAG:*mceF*, pLV-iVSV-G, and pCMV-  
116 R8.2 using FUGENE6 (Promega), and incubated at 37°C, 5% CO<sub>2</sub> for 24 hours.  
117 The media was replaced and the plates were incubated for a further 48 hours. The  
118 supernatant containing virus was harvested, filtered (0.45 µm) and polybrene (5  
119 mg/mL) was added. Supernatant were added to 2 x 10<sup>5</sup> cells/well of HeLa CCL2  
120 cells in 6 well plates with DMEM + 10% FCS. Following selection with 5 µg/mL of  
121 puromycin (Gibco), cells were single sorted at The Doherty Institute Flow  
122 Cytometry Facility into 96 well plates (Corning) and incubated with DMEM + 20%  
123 FCS at 37°C, 5% CO<sub>2</sub> to expand. Clones were selected and screened for protein  
124 expression by the addition of doxycycline at 20 ng/mL for 48 hours. Doxycycline  
125 induction time was adjusted as required.

126

### 127 **SDS-PAGE and Immunoblot analysis**

128 All protein samples were lysed using SDS loading dye by incubating at 95°C for  
129 10 minutes unless otherwise stated. Lysed proteins were separated on NuPAGE  
130 Bis-Tris gels (Life Technologies) with MES running buffer (Life Technologies).  
131 Protein gels were transferred to a nitrocellulose membrane using the iBlot2 system  
132 (Life Technologies). Membrane was blocked in either TBS + 0.1% Tween-20

133 (TBST)+ 5% (w/v) skim milk powder or TBST + 5% (w/v) BSA to match primary  
134 antibody solutions, for 1 hour at RT. Relevant primary antibodies (Mouse anti-  
135 FLAG, Sigma-Aldrich, 1:2000; Rabbit anti-NDUFAF2, Michael Ryan laboratory,  
136 Monash University, 1:1000; Rabbit anti-Mfn2, Michael Ryan laboratory, Monash  
137 University, 1:200; Rabbit anti-TIM29, Sigma-Aldrich, 1:1000; Rabbit anti-CoxIV,  
138 Cell Signaling, 1:1000; Mouse anti-Cytochrome c, BD Biosciences, 1:300; Rabbit  
139 anti-GPX4, Sigma-Aldrich, 1:1000) were incubated with the membrane overnight  
140 at 4°C with mild rotation. Relevant secondary antibodies (Goat anti-Mouse IgG –  
141 HRP, Perkin Elmer, 1:3000; Goat anti-Rabbit IgG – HRP, Perkin Elmer, 1:3000)  
142 were added to the membrane for 1 hour at RT. The membrane was developed  
143 using Clarity Western ECL Reagents (BioRad) and detected with MF-ChemiBIS,  
144 version 3.2 (DNR Bio-Imaging Systems, Ltd.) or Amersham Imager (AI) 600  
145 imager (GE Healthcare). Images were processed using Fiji software.

146

#### 147 **Measurement of Mitochondrial Respiration**

148 Oxygen consumption rate (OCR) was measured using the XF96 analyzer with XF  
149 Cell Mito Stress Test kit according to manufacturer instructions (Seahorse  
150 Bioscience, MA, USA). Briefly,  $2 \times 10^4$  cells/well of <sup>3xFLAG</sup>MceF or empty vector  
151 stable cell lines were plated in Seahorse XF Cell Culture Microplate (96 wells) and  
152 incubated in DMEM + 10% FCS at 37°C, 5% CO<sub>2</sub>. Induced expression occurred  
153 by the addition of 20 nM/mL of doxycycline for 24 and 2 hours before the addition  
154 of the assay medium. Prior to the treatments, the assay medium (Seahorse XF  
155 DMEM, pH 7.4) was supplemented with 1 mM pyruvate (Gibco), 2 mM glutamine  
156 (Sigma-Aldrich), and 10 mM glucose (Sigma-Aldrich). The sensor cartridge was  
157 loaded with Oligomycin (Sigma-Aldrich), Carbonyl cyanide-4 (trifluoromethoxy)  
158 phenylhydrazone (FCCP, Sigma-Aldrich), and Rotenone/Antimycin A (Sigma-  
159 Aldrich). The oxygen consumption ratio (OCR, pmol/min) was monitored in real-  
160 time, with sequential treatments of 1 μM Oligomycin (ATP synthase inhibitor), 1  
161 μM FCCP (mitochondrial uncoupler), and 1 μM Rotenone/Antimycin A (Complex I  
162 and III inhibitors) that were auto-injected into the experimental wells, followed by  
163 three measurement cycles. Data from Wave (Seahorse Wave Desktop Software)

164 were exported to Excel for further calculations. Basal respiration (OCR1 – OCR4),  
165 maximum respiration (OCR3 – OCR4), the percentage of the spare respiratory  
166 capacity  $((OCR3/OCR1) \times 100)$ , proton leak (OCR2 – OCR4), ATP production  
167 (OCR1 – OCR2), non-mitochondrial respiration (OCR4) and coupling efficiency  
168  $((ATP \text{ production rate}/\text{Basal respiration rate}) \times 100)$  were calculated.

169

### 170 **Cytometric measurement of mitochondrial ROS**

171 To detect mitochondrial superoxide generation, a specific mitochondrial  
172 superoxide indicator, MitoSOX™ Red (Molecular Invitrogen Probe), was used  
173 according to the manufacturer's instructions. Briefly,  $1 \times 10^6$  3xFLAGMceF cells/mL  
174 were seeded in 10 cm dishes (Corning). Cells were induced with 20 nM/mL  
175 doxycycline 24 hours prior to ROS induction. Media was then replaced with 1  $\mu$ M  
176 rotenone for a further 20 hours or with 0.1  $\mu$ M Antimycin A (AA) for 4 hours. Next,  
177  $1 \times 10^6$  cells/mL were harvested and incubated with 5  $\mu$ M MitoSOX for 30 minutes  
178 at 37°C with mild agitation. Additionally, cells were incubated with Ghost Dye™  
179 Red 780 (Tonbo Bioscience) for 20 minutes on ice and washed twice. Flow  
180 cytometry analysis (BD FACS Canto II) was performed at The Doherty Institute  
181 Flow Cytometry Facility. MitoSOX Red dye was laser excited at 488 nm and data  
182 were collected at 585/42 nm, while Ghost Dye™ Red 780 was laser excited at 640  
183 nm and data were collected at 780-60 nm.

184

### 185 ***C. burnetii* infection of tissue culture cells**

186 Infections of THP-1 and HeLa cells with *C. burnetii* were performed as previously  
187 described<sup>31</sup>. Briefly, for THP-1 cells, cells were seeded at  $5 \times 10^5$  cells/well in 24-  
188 well plates and were differentiated with 10 nM phorbol 12-myristate 13-acetate  
189 (PMA, Adipogen Life Sciences) for 3 days before being infected at a multiplicity of  
190 infection (MOI) of 5. In comparison, HeLa cells were seeded at  $2 \times 10^4$  cells/well  
191 in 24-well plates the day before infection at an MOI of 5. On the day of infection,  
192 axenic cultures of *C. burnetii* were harvested and genome equivalents were  
193 quantified by qPCR using oligonucleotides specific for *ompA*<sup>83,84</sup>. Following the  
194 addition of *C. burnetii*, cells were centrifuged at 500 x g for 30 minutes at 30°C,

195 before being washed twice with PBS and given fresh media + 5% FCS. At desired  
196 times post-infection, samples were lysed with distilled water and centrifuged to  
197 obtain the cell pellet. gDNA was extracted using the Quick DNA MiniPrep Kit (Zymo  
198 Research) according to the manufacturer's protocol. qPCR reactions were set up  
199 in MicroAmp Fast Optical 96-well reaction plates using the SensiFast SYBR No-  
200 ROX kit (Bioline) and *C. burnetii ompA* specific oligonucleotides. Serial dilutions of  
201 *C. burnetii* gDNA were used as standards. Genomes were quantified in real-time  
202 using the QuantStudio7 Flex RT-PCR system (Thermo Fisher Scientific).

203

#### 204 **Infection of *Galleria mellonella***

205 *G. mellonella* larvae were cultured in-house and kept at 30°C. Infections were  
206 conducted as described previously<sup>26,28,85,86</sup>. Briefly, 10 uL containing 10<sup>6</sup> GE of  
207 relevant *C. burnetii* strains or 10<sup>5</sup> *L. pneumophila* JR32  $\Delta$ *flaA* were injected in the  
208 right proleg of *G. mellonella* larvae. Larvae were incubated at 37°C, and survival  
209 was monitored every 24 hours across 11 days for *C. burnetii* strains and every 12  
210 hours across 10 days for *L. pneumophila*. PBS controls were included with each  
211 experiment and each condition consisted of 10-12 larvae. For bacterial load, live  
212 and dead larvae were collected at the indicated time points and frozen at -20°C.  
213 Larvae were homogenized by bead beating with 5x volume of PBS and *C. burnetii*  
214 GE/mL was determined by qPCR as mentioned above.

215

#### 216 **Immunoprecipitation and LC-MS analysis of 3xFLAG-MceF interactome**

217 Following a 24 hours induction period with doxycycline, whole-cell lysates were  
218 solubilized in a buffer containing 100 mM Tris pH 7.4, 250 mM NaCl, 50% glycerol,  
219 0.5 mM EDTA and 1% digitonin. Lysates were applied to pre-washed anti-FLAG-  
220 M2 magnetic beads and incubated at 4°C for 2 hours under mild agitation. Bound  
221 proteins were washed 3 times with cold PBS and prepared for mass spectrometry  
222 analysis.

223

224 S-Trap<sup>TM</sup> Micro spin column digestion protocol (Protifi<sup>TM</sup>) was used for sample  
225 processing. Briefly, beads were resuspended in 50  $\mu$ L of SDS solubilization buffer

226 (5% SDS, Sigma-Aldrich), 50 mM triethylammonium bicarbonate (TEAB, Sigma-  
227 Aldrich, pH 8). Samples were reduced by adding 20 mM of dithiothreitol (Sigma-  
228 Aldrich, for 10 minutes at 95°C and alkylated by the addition of 40 mM of  
229 iodoacetamide (Sigma-Aldrich) for 30 minutes in the dark at RT. Samples were  
230 acidified with 1.2% (v/v) of phosphoric acid (Sigma-Aldrich) and the undissolved  
231 matter was removed by centrifugation for 8 min at 13,000 x g and beads were  
232 separated using magnetic racks. A volume of 165 µL of S-Trap binding buffer (90%  
233 aqueous methanol (Sigma-Aldrich), 100 mM final TEAB, pH 7.1) was added to the  
234 acidified lysate. Sample mixes were added into the spin columns and centrifuged  
235 at 4000 x g until all solution had passed through. Columns were washed 3 times  
236 by centrifuging through 150 µL S-Trap binding buffer. Twenty µL of trypsin at 1:25  
237 enzyme:protein (ug:ug) in digestion buffer (50 mM TEAB) were added into the  
238 columns and incubated for 1 hour at 47 °C in a thermomixer without agitation.  
239 Peptides were eluted with 40 µL each of 50 mM TEAB and then 0.2% aqueous  
240 formic acid. Hydrophobic peptides were eluted with 35 µL of 50% acetonitrile and  
241 0.2% formic acid. All centrifugations occurred as mentioned above and elutions  
242 were dried down with a spin vacuum before proceeded to stage tip clean up as  
243 mentioned above.

244

245 Dried digests were resuspended in Buffer A and separated using a two-column  
246 chromatography setup composed of a PepMap100 C18 20 mm x 75 µm trap and  
247 a PepMap C18 500 mm x 75 µm analytical column (Thermo Fisher Scientific).  
248 Samples were concentrated onto the trap column at 5 µL/min for 5 minutes with  
249 Buffer A (0.1% formic acid) and then infused into a Orbitrap Exploris 480 Mass  
250 Spectrometer (Thermo Fisher Scientific) at 300 nL/minute via the analytical column  
251 using a Dionex Ultimate 3000 UPLC (Thermo Fisher Scientific). 125-minute  
252 analytical runs were undertaken by altering the buffer composition from 2% Buffer  
253 B (0.1% formic acid, 80% acetonitrile) to 23% B over 95 minutes, then from 23%  
254 B to 40% B over 10 minutes, then from 40% B to 80% B over 5 minutes. The  
255 composition was held at 80% B for 5 minutes, and then dropped to 2% B over 0.1  
256 of a minute before being held at 2% B for another 9.9 minutes. The Exploris 480




257 Mass Spectrometer was operated in a data-dependent mode automatically  
258 switching between the acquisition of a single Orbitrap MS scan (300-1600 m/z,  
259 maximal injection time of 25 ms, an Automated Gain Control (AGC) set to 300%  
260 and a resolution of 120k) and up to 3 seconds of HCD MS/MS scans of precursors  
261 (Stepped NCE of 27;32 and 36%, a maximal injection time of 65 ms, an AGC set  
262 to 400% and a resolution of 30k).

263

### 264 **Proteomic analysis**


265 Immunoprecipitation samples were searched using MaxQuant (v1.6.17.0)<sup>3</sup> and  
266 against the Human proteome (Uniprot accession: UP000005640) and CBU1543  
267 protein sequence (NCBI accession: NP\_820526.1). Searches were undertaken  
268 using “Trypsin” enzyme specificity with carbamidomethylation of cysteine as a  
269 fixed modification. Oxidation of methionine and acetylation of protein N-termini  
270 were included as variable modifications and a maximum of 2 missed cleavages  
271 allowed. To enhance the identification of peptides between samples, the Match  
272 between Runs option was enabled with a precursor match window set to 2 minutes  
273 and an alignment window of 20 minutes with the label free quantitation (LFQ)  
274 option enabled<sup>4</sup>. The resulting outputs were processed within the Perseus  
275 (v1.6.0.7) analysis environment<sup>5</sup> to remove reverse matches and common protein  
276 contaminants and non-mitochondrial host proteins prior to further analysis. For  
277 LFQ comparisons biological replicates were grouped and missing values were  
278 then imputed based on the observed total peptide intensities with a range of  $0.3\sigma$   
279 and a downshift of  $2.5\sigma$  using Perseus. Student t-tests were undertaken to  
280 compare the proteomes between groups with the resulting data exported and  
281 visualized using ggplot2<sup>6</sup> within R. The resulting MS data and search results have  
282 been deposited into the PRIDE ProteomeXchange Consortium repository<sup>7,8</sup> and  
283 can be accessed with the identifier: PXD030191 using the Username:  
284 reviewer\_pxd030191@ebi.ac.uk and Password: Hr6uHdoK.

285



286

287 **Figure Supplementary 1. Translocation of CBU1543 is Dot/Icm-dependent.** HeLa  
 288 CCL2 cells were infected with WT or *lcmL* mutant *C. burnetii* NMII expressing CBU1543  
 289 (A) or MceA (B) fused to TEM1 at an MOI 500 for 24 hours. After 20 hours, cells were  
 290 treated with MnCl<sub>2</sub> as indicated for 2 hours before loading with CCF2-AM and incubating  
 291 at RT for a further 2 hours. 'Fold change' is the increase in corrected 450/520 ratio (see  
 292 methods) compared to uninfected cells. Bar graphics represent the averages of results of  
 293 three independent experiments and error bars are standard deviation (SD). Statistical  
 294 analyses were performed by two-way ANOVA with the Tukey test for multiple  
 295 comparisons. When *p* value was considered statistically significant (*p*<0.05), its value was  
 296 stated in the figure.  
 297



298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312

**Figure Supplementary 2: MceF-cytoprotective effects enhance mitochondrial Spare Respiratory Capacity.** (A) Schematic representation of Oxygen Consumption Rate (OCR) levels (y-axis) versus time (x-axis). Oligomycin, FCCP, and rotenone/antimycin A (AA) were sequentially injected as indicated (black arrows). (B) Targets of each compound in the electron transport chain. (A-B) Created with BioRender.com. (C-I)  $3^x$ FLAG<sub>MceF</sub> stable cell line was induced for effector expression for 2 and 24 hours with doxycycline. (C) Experimental OCR in  $3^x$ FLAG<sub>MceF</sub> stable cell lines, (D) Basal respiration (OCR1-OCR4), (E) Maximal respiration (OCR3-OCR4), (F) Proton leak (OCR2-OCR4), (G) ATP-linked production (OCR1-OCR2), (H) Non-mitochondrial respiration (OCR4) and (I) Percentage of the coupling efficiency ((ATP rate/Basal rate) $\times$ 100). Curve and bar graphics represent the mean result of three independent experiments with individual data points shown. Error bars represent standard deviation (SD). Statistical analyses were performed by one-way ANOVA with the multiple comparison test of Bonferroni. When  $p$  value was considered statistically significant ( $p < 0.05$ ), its value was stated in the figure.

**Table S1. Plasmids used in this study.**

| Plasmid                      | Features   | Antibiotic selection | References                                |
|------------------------------|--|----------------------|---|
| pcDNA4/TO:3xFLAG             | Eukaryotic expression vector encoding 5' 3xFLAG tag and multiple cloning site (MCS)  | AmpR                 | Clontech, Roy Laboratory, Yale University |
| pcDNA4/TO:3xFLAG:CBU1543     | Encodes 5' 3xFLAG tag and full length of <i>cbu1543</i> with 5' BamHI and 3' XhoI restriction endonuclease (RE) sites  | AmpR                 | Newton Laboratory                         |
| pGEM-T Easy                  | High copy cloning vector   | AmpR                 | Promega                                   |
| pJB-CAT:Blam-MCS             | <i>C. burnetii</i> expression vector encoding 5' BLAM under constitutive expression by the <i>C. burnetii</i> P1169 promoter. The multiple cloning site (MCS) from pcDNA4/TO:3xFLAG was inserted within the Sall site. | CmR                  | Newton Laboratory                         |
| pJB-CAT:Blam-MCS:CBU1543     | <i>C. burnetii</i> expression vector encoding 5' BLAM:CBU1543 under constitutive expression by the <i>C. burnetii</i> P1169 promoter.  | CmR                  | This study                                |
| pJB-CAT:Blam:CBU0077         | <i>C. burnetii</i> expression vector encoding 5' BLAM:CBU0077 under constitutive expression by the <i>C. burnetii</i> P1169 promoter. <i>cbu0077</i> gene was inserted within Sall site.                               | CmR                  | Newton Laboratory                         |
| pJB-Kan:3xFLAG               | <i>C. burnetii</i> expression vector encoding 5' 3xFLAG tag under constitutive expression by the <i>C. burnetii</i> P1169 promoter   | KanR                 | <sup>9</sup>                              |
| pJB-CAT:3xFLAG               | <i>C. burnetii</i> expression vector encoding 5' 3xFLAG tag under constitutive expression by the <i>C. burnetii</i> P1169 promoter   | CmR                  | <sup>9</sup>                              |
| pJB-CAT:3xFLAG:CBU1543       | Full length of <i>cbu1543</i> with 5' Sall and 3' Sall restriction RE sites  | CmR                  | Newton Laboratory                         |
| pF_TRE3G_Puro                | Eukaryotic expression vector under inducible expression by doxycycline   | AmpR                 | Silke Laboratory, WEHI                    |
| pF_TRE3G_Puro:3xFLAG:CBU1543 | Encodes 5' 3xFLAG tag and full length of <i>cbu1543</i>  | AmpR /Puromycin      | This study                                |

|                     |   |                   |  |
|---------------------|---|-------------------|--|
|                     | with 5' BamHI and 3' NheI RE sites  |                   |  |
| pLV-iVSV-G          | Lentiviral expression plasmid designed to expresses a viral envelope gene   | AmpR              | Silke Laboratory, WEHI                         |
| pCMV-R8.2           | lentiviral expression plasmid for packaging   | AmpR              | Silke Laboratory, WEHI                         |
| pJC-CAT             | <i>C. burnetii</i> vector for gene inactivation   | CmR               | 10   |
| pJC-CAT:CBU1543     | Upstream (1.5 kb) and downstream (1,5 kb) of <i>cbu1543</i> with 5' BamHI and 3' Sall restriction RE sites  | CmR               | This study                                     |
| pJC-CAT-Kan:CBU1543 | Upstream (1.5 kb) and downstream (1,5 kb) regions of <i>cbu1543</i> with 5' BamHI and 3' Sall restriction RE sites  | CmR/KanR          | This study                                     |
| lentiGuide-puro:gp4 | Expresses <i>Streptococcus pyogenes</i> CRISPR chimeric RNA element with customizable ( <i>gp4</i> ) sgRNA from U6 promoter and puromycin resistance from EF-1a promoter. Third generation lentiviral backbone. | AmpR /Puromycin   | This study                                     |
| psPAX2              | (Empty Backbone) 2nd generation lentiviral packaging plasmid. Can be used with 2nd or 3rd generation lentiviral vectors and envelope expressing plasmid.  | AmpR              | Zamboni Laboratory                             |
| pMD2.G              | VSV-G envelope expressing plasmid   | AmpR              | Zamboni Laboratory                             |
| pENTR223-GPX4       | Glutathione peroxidase 4 cDNA clone   | Spec <sup>R</sup> | The ORFeome collaboration, DNASU <sup>11</sup> |
| pLJM1-GFP-GPX4      | GPX4 cDNA cloned downstream of GFP  |                   | This study                                     |

314

315

316  
317

**Table S2. Oligonucleotides used in this study.**

| Description of purpose   | Sequence (5' to 3')                           |
|--|---|
| <b>Sequencing primers for pcDNA4/TO derivatives</b>                        |   |
| pcDNA4_F   | CGCAAATGGGCGGTAGGCGTG                         |
| pcDNA4_R   | CTAGAAGGCACAGTCGAGG                           |
| <b>Sequencing primers for pJB-CAT:BLAM derivatives</b>                     |   |
| pJB-CAT:BLAM_F   | CCTTCATGAAGGAGGCTG                            |
| pJB-CAT:BLAM_R   | CCCTGGGTGAGTTTCACC                            |
| <b>Sequencing primers for pJB-CAT derivatives</b>                          |   |
| pJB-CAT_F  | CCTTCATGAAGGAGGCTG                            |
| pJB-CAT_R  | CCCTGGGTGAGTTTCACC                            |
| <b>Sequencing primers for pJC-CAT derivatives</b>                          |   |
| pJC-CAT_F  | GTGAGCGAGGAAGCGGAAG                           |
| pJC-CAT_R  | CAGGAGATAAGAACGCATCA                          |
| <b>Sequencing primers for Kan<sup>R</sup> gene</b>                         |   |
| Kan <sup>1</sup>   | GATGGAAGCCGGTCTTGTCGAT                        |
| Kan <sup>2</sup>   | CGGACAGGTCGGTCTTGACAAAA                       |
| <b>qPCR quantification of <i>C. burnetii</i> genomes</b>                   |   |
| <i>ompA</i> _F   | CAGAGCCGGGAGTCAAGCT                           |
| <i>ompA</i> _R   | CTGAGTAGGAGATTTGAATCGC                        |
| <b>Eukaryotic expression vector constructs - pFTRE</b>                     |   |
| 3xFLAG_F (BglIII)  | AAAGATCTATGGACTACAAAGACCATGAC                 |
| <i>cbu1543</i> _R (NheI)   | ATTGCTAGCTCATTTTCCAAGGGACTC                   |
| <b><i>cbu1543</i> primers for gene inactivation in <i>C. burnetii</i></b>  |   |
| Forward primer to amplify 1.5 kb region upstream to <i>cbu1543</i> (BamHI) | AAGGATCCATATTTAAATAATGAGGA                    |
| Reverse primer to amplify 1.5 kb region upstream <i>cbu1543</i> (NotI)     | TTTCCAAAAGTTTTAGCGGGCGGCCGCTATCTTGCCTCGTTGCTT |
| Forward primer to amplify 1.5 kb region downstream <i>cbu1543</i> (NotI)   | AAGCAACGAGGCAAGATAGCGGCCGCGCTAAAACCTTTTGAAA   |
| Reverse primer to amplify 1.5 kb region downstream <i>cbu1543</i> (Sall)   | AAGTCGACTTCTCGGGGTCTCGTTGT                    |
| Forward primer to amplify Kan from pJB-Kan with P1169 (NotI)               | GACGCGGCCGAGCTTATGGCTTCGTTTCGCAG              |
| Reverse primer to amplify Kan from pJB-Kan (NotI)                          | GACGCGGCCGCTCAGAAGAACTCGTCAAGAAGGCG           |
| Forward internal primer to sequence pJC-CAT-15435'3'                       | CGGTTGTTTAAAAGATATTCG                         |
| Reverse internal primer to sequence pJC-CAT-15435'3'                       | GGTTTAATTCACATGGCCG                           |

| <b>Double-stranded guide RNA (gRNA) targeting <i>gpx4</i></b>    |  |
|--|--|
| sgRNA1 5'3'  | CGTGTGCATCGTCACCAACG                       |
| sgRNA2 5'3'  | CATGCCCGATATGCTGAGTG                       |
| <b>pJB-CAT <i>C. burnetii</i> effector expression constructs</b> |  |
| CBU0041 F  | CGATGACAAGGTGCACATGAGGGATGGCACTACACG       |
| CBU0041 R  | GCATGCCTCAGTCGACTTATCCGCTCAACGAATGTGG      |
| CBU0077 F  | CGATGACAAGGTGCACATGAGACAACCTCGTTTCAATTTAAA |
| CBU0077 R  | GCATGCCTCAGTCGACTTACATAATAGAACACCCACGA     |
| CBU0080 F  | CGATGACAAGGTGCACTTGGGTCATCGTGAGAAAGAA      |
| CBU0080 R  | GCATGCCTCAGTCGACTTATTGAAATGCTCTCGTCTGG     |
| CBUK1976 F   | CGATGACAAGGTGCACATGAGGCACGAAAATCCCCA       |
| CBUK1976 R   | Used CBU0080 R                             |
| CBU0113 F  | GACGGATCCATGTCGGCAACCCAACCTTTTAA           |
| CBU0113 R  | GACGAATTCTAGCCCCCTGGAGCTGGA                |
| CBU0175 F  | CGATGACAAGGTGCACATGTTAATGGCTTATATGAGGC     |
| CBU0175 R  | GCATGCCTCAGTCGACTTAATCCCATTCAATATTTTCTAAA  |
| CBU0295 F  | CGATGACAAGGTGCACTTGAAGTACAAGCGACACATG      |
| CBU0295 R  | GCATGCCTCAGTCGACTTAAAAAGTAAAGGATTGTTTAGAG  |
| CBU0590 F  | GACGGATCCATGAACACAAGAGAGACACTTGCC          |
| CBU0590 R  | GACGAATTCTTAGACCGTTTTAGGCTCTGTCAT          |
| CBU0635 F  | CGATGACAAGGTGCACATGCGAGAGGAAAAAGAGGA       |
| CBU0635 R  | GCATGCCTCAGTCGACCTAAACTAATGTCATTAACGGT     |
| CBU0781 F  | CGATGACAAGGTGCACATGAGTAGACGTGAGACTCC       |
| CBU0781 R  | GCATGCCTCAGTCGACTCACCGAGGACTAGACAGAC       |
| CBU0794 F  | CGATGACAAGGTGCACATGAAAATTATTAATTAGTGAAAA   |
| CBU0794 R  | GCATGCCTCAGTCGACTTATCTAAATCTGGCTTTTTGC     |
| CBU0801 F  | CGATGACAAGGTGCACGTGAAAATTCGAAACTGGATTAA    |
| CBU0801 R  | GCATGCCTCAGTCGACCTAAAAATTTAAATTAATACCAATG  |
| CBU0881 F  | CGATGACAAGGTGCACATGCCAATAATGAGCCCCA        |
| CBU0881 R  | GCATGCCTCAGTCGACCTACCTGAGGGACTTATACC       |
| CBU0937 F  | CGATGACAAGGTGCACGTGACTTGTGACAGGGTTGT       |
| CBU0937 R  | GCATGCCTCAGTCGACTTAAAAATAAAGATCGAACTGTG    |
| CBU1213 F  | CGATGACAAGGTGCACATGAGAGAATCATCAGAAAATCA    |
| CBU1213 R  | GCATGCCTCAGTCGACCTAAATTCCAAAAGAACCCGG      |
| CBU1217 F  | CGATGACAAGGTGCACATGAGAACTTCGCATCAAATC      |
| CBU1217 R  | GCATGCCTCAGTCGACTCACTTTCTGGAAAAAGGGGC      |
| CBU1253 F  | CGATGACAAGGTGCACATGGCGAAATTTACTATACGTTAG   |
| CBU1253 R  | GCATGCCTCAGTCGACTTACGCAGCGCGCATGGTT        |
| CBU1314 F  | CGATGACAAGGTGCACGTGTATAAAAAATGGAGGTTACC    |
| CBU1314 R  | GCATGCCTCAGTCGACTCACGATCGCTTGGCAGGC        |
| CBU1379 F  | CGATGACAAGGTGCACATGTCGTCGTCAATCCCAAC       |
| CBU1379 R  | GCATGCCTCAGTCGACCTAGGCTGCTTTCATTCCAG       |
| CBU1387 F  | GACGGATCCATGCCCAATAAGGAACCCGAATC           |
| CBU1387 R  | GACGAATTCTCACTTTGGAGTCAACCTTGTGG           |
| CBU1425 F  | CGATGACAAGGTGCACATGAAAAAATCGCAACTATTGG     |
| CBU1425 R  | GCATGCCTCAGTCGACTTATCGAATGATCTTCCATTGT     |
| CBU1457 F  | CGATGACAAGGTGCACATGCCTTACCCTTACGAAGC       |
| CBU1457 R  | GCATGCCTCAGTCGACTCATGTTTTTACCCTATCATTAC    |
| CBU1460 F  | CGATGACAAGGTGCACATGTCTAGTTTTGGCGATGCT      |
| CBU1460 R  | GCATGCCTCAGTCGACTTACATTTGCTTACAACACGGA     |
| CBU1485 F  | CGATGACAAGGTGCACATGCCTGGAGGTTGCATTATG      |
| CBU1485 R  | GCATGCCTCAGTCGACTTAGAATCGAGGGCGATGTAA      |
| CBU1493 F  | CGATGACAAGGTGCACATGAGTCGCAAAAACATACCAG     |

|            |   |
|------------|---|
| CBU1493 R  | GCATGCCTCAGTCGACTTAGGAGCAAGTACAGGTTGT       |
| CBU1524 F  | CGATGACAAGGTTCGACATGAACACAAGTCCTACATCAA     |
| CBU1524 R  | GCATGCCTCAGTCGACCTATGTCTTTTGGGAGCGT         |
| CBUD0462 F | CGATGACAAGGTTCGACATGAGAAAAAACCTAACGTCG      |
| CBUD0462 R | Used CBU1524 R                              |
| CBU1532 F  | CGATGACAAGGTTCGACTTGGCAGGCATAGCTGCAAC       |
| CBU1532 R  | GCATGCCTCAGTCGACTTACTTATTAATTCGGGTATGTA     |
| CBUD0454 F | CGATGACAAGGTTCGACTTGCAGACGAGAACGATCC        |
| CBUD0454 R | Used CBU1532 R                              |
| CBU1543 F  | CGATGACAAGGTTCGACATGCAACCCACCGCAGAGA        |
| CBU1543 R  | GCATGCCTCAGTCGACTCATTTCGAAGGGACTCGC         |
| CBU1556 F  | CGATGACAAGGTTCGACATGCCTTCTGATAGAAACGG       |
| CBU1556 R  | GCATGCCTCAGTCGACCTAACGGGAGCATAATTAACC       |
| CBU1566 F  | AAGGATCCATGCCTTCTGATAGAAACGG                |
| CBU1566 R  | AAGAATTCCTAACGGGAGCATAATTAACC               |
| CBU1569 F  | CGATGACAAGGTTCGACATGCCTATTACCAGCTTAGAAT     |
| CBU1569 R  | GCATGCCTCAGTCGACTTAATTGTTATTTTCGAGGAGAG     |
| CBU1636 F  | CGATGACAAGGTTCGACATGACCTGGAAATTAATGAGAT     |
| CBU1636 R  | GCATGCCTCAGTCGACCTAAAGAACCAGCCCGCTT         |
| CBU1751 F  | CGATGACAAGGTTCGACATGGGTAGAGTTTTTTCGTACA     |
| CBU1751 R  | GCATGCCTCAGTCGACTTAAGGCCTTGCGGGTTCG         |
| CBU1752 F  | AAGTCGACATGAGAGATCCAGATCAAGAAA              |
| CBU1752 R  | AAGTCGACTTATGAAGGGCCGAATGCCG                |
| CBU1769 F  | CGATGACAAGGTTCGACATGACGAATGAAGATTTTTTAATC   |
| CBU1769 R  | GCATGCCTCAGTCGACCTATGCTAAATTTTCGGACCAAT     |
| CBU1823 F  | CGATGACAAGGTTCGACATGCCTAAACTCAGTAACCGT      |
| CBU1823 R  | GCATGCCTCAGTCGACTTATGGCCTCTATTTGTTGGC       |
| CBU1863 F  | CGATGACAAGGTTCGACATGCGAAATGATGATGATACTC     |
| CBU1863 R  | GCATGCCTCAGTCGACTTACGCAGTAAGTGCAGAAGG       |
| CBU1963 F  | CGATGACAAGGTTCGACATGGAGTTTCTAATAAAGTTTTCT   |
| CBU1963 R  | GCATGCCTCAGTCGACTCAAGGATGATGGTGGCGAG        |
| CBUD2063 F | CGATGACAAGGTTCGACATGCGAGTTGAGCTGTGGC        |
| CBUD2063 R | Used CBU1963 R                              |
| CBU2013 F  | AAGGATCCATGCCATCGATAAATTTGACGA              |
| CBU2013 R  | AACTCGAGTTAAGAAACTAGCTGAAGATGAG             |
| CBU2016 F  | AAGGATCCATGGTGGTTATGCTAGAAGAC               |
| CBU2016 R  | AACTCGAGTTAGGGATCGAAGCCGGAG                 |
| CBU2052 F  | CGATGACAAGGTTCGACATGCCTAAAAACACAAATCCAG     |
| CBU2052 R  | GCATGCCTCAGTCGACTTATTTCAAAAAGCATTTACAAGA    |
| CBU2056 F  | CGATGACAAGGTTCGACGTGGTGAGTTTAATTTTCATAAAG   |
| CBU2056 R  | GCATGCCTCAGTCGACCTAAGGTGCGGGTGCGC           |
| CBU2078 F  | CGATGACAAGGTTCGACATGTTCAAACCCCTATTCCAAA     |
| CBU2078 R  | GCATGCCTCAGTCGACCTACTTAGCTGATTTCTCTTTTA     |
| CBUA0006 F | CGATGACAAGGTTCGACATGCGTATGTTTCAGAGAAAGC     |
| CBUA0006 R | GCATGCCTCAGTCGACTTATGGATTCTTACTTCTCAAAG     |
| CBUA0013 F | CGATGACAAGGTTCGACATGCCATATTTTTTTTACACTACC   |
| CBUA0013 R | GCATGCCTCAGTCGACCTATCTGGAACAGAAGGGAAA       |
| CBUA0015 F | CGATGACAAGGTTCGACGTGGTAAAAGCCAAGGACTTA      |
| CBUA0015 R | GCATGCCTCAGTCGACTTAAGTTAATTTTATTTGATTTTTAGT |
| CBUA0016 F | CGATGACAAGGTTCGACATGAGATTAGAACAACCAAGAAA    |
| CBUA0016 R | GCATGCCTCAGTCGACTTAGCAAAGTCTGAAAGAAGGA      |
| CBUA0020 F | ACGTCGACATGAATGATGATGAGAAAAAAAAGC           |
| CBUA0020 R | GGGTCGACTTACTTATTAATTCGGGTA                 |



|            |  |
|------------|--|
| CBUA0023_F | CGATGACAAGGTTCGACATGAAAGATTATGTTAAAGAAATTC |
| CBUA0023_R | GCATGCCTCAGTCGACCTATCCGATACCAGGCC          |
| CBUD0054_F | CGATGACAAGGTTCGACGTGTATGCAAACCATTTGATAC    |
| CBUD0054_R | GCATGCCTCAGTCGACCTATTTTTTTGTCATTTCCAGATT   |
| CBUD0231_F | CGATGACAAGGTTCGACATGCCATTAAGACTTACGC       |
| CBUD0231_R | GCATGCCTCAGTCGACTTACTTTATAAAGTCCGTGTATA    |
| CBUD0461_F | CGATGACAAGGTTCGACATGTCCCGTCGCGAGCCT        |
| CBUD0461_R | GCATGCCTCAGTCGACTTAAATCGTAAGGCGCTTTGTT     |
| CBUD0588_F | AAGGATCCGTGACTCTCATGTTTCGAGC               |
| CBUD0588_R | AAGAATTCTCATTGAAGTTGAACGGTTC               |
| CBUD0997_F | AAGGATCCATGAAAATGAAGGCAATGGAAG             |
| CBUD0997_R | AACTCGAGTTAGATTTTAGTTACTGGACGC             |
| CBUD1019_F | CGATGACAAGGTTCGACTTGTGAGAATTAGGAGGGAT      |
| CBUD1019_R | GCATGCCTCAGTCGACTTAGATTAACGTGCGCGTATAA     |
| CBUD1627_F | CGATGACAAGGTTCGACATGAGACAGCGTGAAATTAATG    |
| CBUD1627_R | GCATGCCTCAGTCGACCTACCGCTGGAAGCCGCG         |
| CBUD1656_F | CGATGACAAGGTTCGACATGAGGAGAAATATCATGGCAA    |
| CBUD1656_R | GCATGCCTCAGTCGACTTATCGACCGGAAACGGA         |
| CBUD1750_F | CGATGACAAGGTTCGACATGGTTGCAAAAAAGAGTGTG     |
| CBUD1750_R | GCATGCCTCAGTCGACTTATCTGCGTTGCAATCGGG       |
| CBUD2034_F | CGATGACAAGGTTCGACTTGCTTAGCTTAATGGCCAGC     |
| CBUD2034_R | GCATGCCTCAGTCGACTTAAACAGTCCGGGGCCTG        |
| CBUD2035_F | CGATGACAAGGTTCGACGTGGGACAAAATACAACGAGG     |
| CBUD2035_R | GCATGCCTCAGTCGACTTAAAGCTAAGCAAGGGGTATTA    |
| CBUD2154_F | CGATGACAAGGTTCGACATGACAAGACAAACAACACTGAAA  |
| CBUD2154_R | GCATGCCTCAGTCGACTCATTGATTGTTAAGGAAGAAG     |
| CBUG1587_F | CGATGACAAGGTTCGACATGAATCAACAACAACGAATACA   |
| CBUG1587_R | GCATGCCTCAGTCGACTTATGTGGATGCGCTGGGC        |
| CBUG1886_F | CGATGACAAGGTTCGACTTGTGGAGATAGTGATGAGAA     |
| CBUG1886_R | GCATGCCTCAGTCGACTCACTTTGGCCGATGATGTTT      |
| CBUK0684_F | CGATGACAAGGTTCGACATGAGTCGCCAACAACGTAAC     |
| CBUK0684_R | GCATGCCTCAGTCGACTTAAAGCAGCGTGCAGCTG        |
| CBUK1330_F | CGATGACAAGGTTCGACATGAGCCGGACCTACAACG       |
| CBUK1330_R | GCATGCCTCAGTCGACTTAAATGCAAACCACCCGATTC     |
| CBUK1690_F | CGATGACAAGGTTCGACTTGGAGGCTATGATGCGTTC      |
| CBUK1690_R | GCATGCCTCAGTCGACCTAATTTTTAAATTCAGGCCCAT    |
| CBUK1907_F | CGATGACAAGGTTCGACATGAGACATCCATAATTCACA     |
| CBUK1907_R | GCATGCCTCAGTCGACTCAAAAAATTAGGACGCCATCC     |

318  
319

320 **SI References**

321

322 Newton, P., Latomanski, E. A. & Newton, H. J. Applying fluorescence resonance  
323 energy transfer (FRET) to examine effector translocation efficiency by *Coxiella*  
324 *burnetii* during siRNA silencing. *Journal of Visualized Experiments* **113**, 1–12  
325 (2016).

326 Altschul, S. F. *et al.* Gapped BLAST and PSI-BLAST: a new generation of protein  
327 database search programs. *Nucleic Acids Res* **25**, 3389–3402 (1997).

328 Cox, J. & Mann, M. MaxQuant enables high peptide identification rates,  
329 individualized p.p.b.-range mass accuracies and proteome-wide protein  
330 quantification. *Nat Biotechnol* **26**, 1367–1372 (2008).

331 Cox, J. *et al.* Accurate proteome-wide label-free quantification by delayed  
332 normalization and maximal peptide ratio extraction, termed MaxLFQ. *Molecular*  
333 *and Cellular Proteomics* **13**, 2513–2526 (2014).

334 Tyanova, S. & Cox, J. Perseus: A Bioinformatics Platform for Integrative Analysis  
335 of Proteomics Data in Cancer Research. *Cancer Systems Biology: Methods and*  
336 *Protocols, Methods in Molecular Biology* **1711**, 133–148 (2018).

337 Wickham, H. *Ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New  
338 York (2016).

339 Vizcaino, J. A. *et al.* 2016 update of the PRIDE database and its related tools.  
340 *Nucleic Acids Res* **44**, D447–D456 (2016).

341 Perez-Riverol, Y. *et al.* The PRIDE database and related tools and resources in  
342 2019: Improving support for quantification data. *Nucleic Acids Res* **47**, D442–D450  
343 (2019).

344 Beare, P. A., Sandoz, K. M., Omsland, A., Rockey, D. D. & Heinzen, R. A.  
345 Advances in genetic manipulation of obligate intracellular bacterial pathogens.  
346 *Front Microbiol* **2**, 1–13 (2011).

347 Beare, P. A., Larson, C. L., Gilk, S. D. & Heinzen, R. A. Two Systems for Targeted  
348 Gene Deletion in *Coxiella burnetii*. *Appl Environ Microbiol* **78**, 4580–4589 (2012).

349 Seiler, C. Y. *et al.* DNASU plasmid and PSI:Biological-Materials repositories:  
350 Resources to accelerate biological research. *Nucleic Acids Res* **42**, (2014).

351

352

353